Catalent Inc (NYSE:CTLT) Given Average Rating of “Buy” by Analysts

Catalent Inc (NYSE:CTLT) has earned a consensus rating of “Buy” from the nine brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $58.67.

A number of brokerages have recently commented on CTLT. Stephens began coverage on shares of Catalent in a report on Thursday, October 17th. They issued an “overweight” rating and a $56.00 target price for the company. Zacks Investment Research cut shares of Catalent from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, ValuEngine cut shares of Catalent from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd.

In other news, SVP Ricardo Pravda sold 2,612 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $52.73, for a total transaction of $137,730.76. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Aristippos Gennadios sold 45,256 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $52.55, for a total transaction of $2,378,202.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 55,512 shares of company stock worth $2,921,998. Company insiders own 1.30% of the company’s stock.

Several institutional investors have recently modified their holdings of CTLT. Penn Capital Management Co. Inc. acquired a new position in Catalent during the second quarter worth about $3,584,000. LPL Financial LLC acquired a new position in Catalent during the second quarter worth about $445,000. M&T Bank Corp acquired a new position in Catalent during the second quarter worth about $329,000. Public Employees Retirement System of Ohio grew its position in Catalent by 13.9% during the second quarter. Public Employees Retirement System of Ohio now owns 56,802 shares of the company’s stock worth $3,079,000 after buying an additional 6,921 shares during the period. Finally, MML Investors Services LLC acquired a new position in Catalent during the second quarter worth about $202,000.

CTLT traded down $0.59 on Friday, reaching $60.88. The company had a trading volume of 774,500 shares, compared to its average volume of 728,725. Catalent has a 1 year low of $34.81 and a 1 year high of $61.94. The stock has a market capitalization of $8.93 billion, a PE ratio of 37.58, a P/E/G ratio of 2.61 and a beta of 1.69. The company has a quick ratio of 1.65, a current ratio of 2.06 and a debt-to-equity ratio of 1.73. The stock has a 50-day moving average price of $55.10 and a 200-day moving average price of $52.90.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, November 5th. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.07. Catalent had a net margin of 5.77% and a return on equity of 15.30%. The firm had revenue of $664.70 million during the quarter, compared to analysts’ expectations of $634.87 million. During the same period in the previous year, the company earned $0.28 earnings per share. Catalent’s quarterly revenue was up 20.5% compared to the same quarter last year. As a group, analysts expect that Catalent will post 1.78 earnings per share for the current fiscal year.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Recommended Story: VIX – Volatility Index

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.